Encodes An Animal Polypeptide Patents (Class 536/23.5)
-
Publication number: 20140273227Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands and polyligands that modulate GSK3 activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.Type: ApplicationFiled: April 17, 2014Publication date: September 18, 2014Applicant: Intrexon CorporationInventors: Thomas D. REED, Amy H. ATZEL
-
Publication number: 20140274874Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: AMGEN INC.Inventors: Randal R. KETCHEM, Jason Charles O'NEILL, Jeonghoon SUN
-
Publication number: 20140274753Abstract: The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ZNF545 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided.Type: ApplicationFiled: March 12, 2013Publication date: September 18, 2014Inventors: JUN YU, Joseph Jao Yiu Sung
-
Publication number: 20140274908Abstract: The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ADAMTS9 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ADAMTS9 gene expression or activity.Type: ApplicationFiled: March 12, 2013Publication date: September 18, 2014Applicant: The Chinese University of Hong KongInventors: JUN YU, Joseph Jao Yiu Sung
-
Publication number: 20140272974Abstract: This invention relates to a novel retroelement, named “Steamer”, found in mollusks, more specifically Mya arenaria, that is associated with haemic neoplasia in these organisms. Haemic neoplasia (HN) is a recognizable leukemic-like disease. The invention provides the retroelement protein, antibodies to the protein, nucleic acids encoding the protein, probes, primer, gene constructs comprising the nucleic acids, host cells comprising the nucleic acids, and methods of using.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Stephen P. Goff, W. Ian Lipkin, Gloria Arriagada, Carol Reinisch, James Sherry, Charles Walker
-
Publication number: 20140275227Abstract: The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: December 20, 2013Publication date: September 18, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephen G. Hoge, Antonin de Fougerolles, Jeff Lynn Ellsworth
-
Publication number: 20140274782Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.Type: ApplicationFiled: March 15, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore
-
Publication number: 20140271692Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Harpreet SINGH, Steffen WALTER, Toni WEINSCHENK, Norbert HILF, Oliver SCHOOR, Claudia TRAUTWEIN
-
Patent number: 8835618Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.Type: GrantFiled: August 15, 2011Date of Patent: September 16, 2014Assignees: Aventis Pharma S.A., Institut National de la Santé et de la Recherche MédicaleInventors: Alexis Brice, Christophe Lucking, Patrice Denefle, Sylvain Ricard, Nacer Eddine Abbas, Sandrine Bouley
-
Patent number: 8835385Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: GrantFiled: March 21, 2012Date of Patent: September 16, 2014Assignee: Amgen Inc.Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
-
Publication number: 20140259233Abstract: Provided are a transporter gene involved in the promotion or inhibition of Cd absorption by roots, a mutant gene thereof and a transporter protein thereof, as well as a rice plant in which Cd absorption is inhibited and a method for selecting and raising a Cd absorption-inhibiting rice plant, which are a gene encoding a transporter protein involved in the regulation of cadmium absorption, which contains the DNA nucleotide sequence shown in SEQ ID NO:2, a gene encoding a transporter protein involved in the regulation of cadmium absorption, which contains the DNA nucleotide sequence shown in SEQ ID NO:3, a gene encoding a transporter protein involved in the regulation of cadmium absorption, which contains the DNA nucleotide sequence shown in SEQ ID NO:4, and a transporter protein involved in the regulation of cadmium absorption, which contains the amino acid sequence of SEQ ID NO:1.Type: ApplicationFiled: October 23, 2012Publication date: September 11, 2014Applicant: NATIONAL INSTITUTE FOR AGRO-ENVIRONMENTAL SCIENCESInventors: Satoru Ishikawa, Masato Kuramata, Tadashi Abe, Masato Igura, Hiromi Nakanishi, Naoko Nishizawa
-
Publication number: 20140255988Abstract: DNA encoding a monomeric variant of red fluorescent protein eqFP611 comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.Type: ApplicationFiled: January 27, 2014Publication date: September 11, 2014Applicant: Universität UlmInventors: Jörg Wiedenmann, Simone Kredel, Franz Oswald, Gerd Ulrich Nienhaus
-
Publication number: 20140255468Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: December 13, 2013Publication date: September 11, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Publication number: 20140255467Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: December 13, 2013Publication date: September 11, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey, Ron Weiss
-
Publication number: 20140256917Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).Type: ApplicationFiled: May 27, 2014Publication date: September 11, 2014Applicants: The United States Government as represented by the Department of Veterans Affairs, Loma Linda UniversityInventors: Kin-Hing William Lau, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan, David J. Baylink
-
Publication number: 20140255437Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.Type: ApplicationFiled: October 25, 2012Publication date: September 11, 2014Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Patent number: 8828937Abstract: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof.Type: GrantFiled: March 11, 2010Date of Patent: September 9, 2014Assignee: Haase Investments UGInventors: Petra Seemann, Stefan Mundlos, Carsten Reissner, Georg Duda, Julia Zimmer
-
Patent number: 8828717Abstract: The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.Type: GrantFiled: November 15, 2010Date of Patent: September 9, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jeffrey Schlom, Eduardo A. Padlan, Rafia Mehdi Kashmiri
-
Publication number: 20140248300Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.Type: ApplicationFiled: May 9, 2014Publication date: September 4, 2014Applicant: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa
-
Publication number: 20140248334Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.Type: ApplicationFiled: February 7, 2014Publication date: September 4, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
-
Publication number: 20140248661Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: ApplicationFiled: April 2, 2014Publication date: September 4, 2014Applicant: ZymoGenetics Inc.Inventors: Scott R. Presnell, Francis J. Grant, Emily C. Costerison, Theodore E. Whitmore
-
Publication number: 20140248641Abstract: The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.Type: ApplicationFiled: October 31, 2013Publication date: September 4, 2014Applicant: NPS PHARMACEUTICALS, INC.Inventors: Donald G. Munroe, Gupta K. Ashwani, Tejal B. Vyas, Kirk McCallum, Ermei Fan
-
Publication number: 20140248631Abstract: The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value.Type: ApplicationFiled: November 14, 2012Publication date: September 4, 2014Inventors: Michael Kiehntopf, Diana Schmerler, Thomas Deufel, Frank Brunkhorst
-
Publication number: 20140249303Abstract: The present invention discloses a functional relationship between a recognized disease condition and a polymorphism in the nucleotide factor kappa B promoter (NFKB1). This relationship provides a platform for methods of altering promoter activity and for determining similar relationships between specific pathologies and identified polymorphisms. A statistically significant risk of developing ulcerative colitis was shown to be correlated with the presence of an ATTG insertion/deletion in the NFKB1 promoter and is likely to apply also to a variety of other inflammatory diseases.Type: ApplicationFiled: October 4, 2013Publication date: September 4, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Steven R. Brant, Amir Karban, Franklin Nouvet, Theodore M. Bayless, James J. Potter, Esteban Mezey, Toshihiko Okazaki
-
Publication number: 20140249072Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.Type: ApplicationFiled: May 4, 2012Publication date: September 4, 2014Applicant: WELLSTAT IMMUNO THERAPEUTICS, LLCInventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
-
Patent number: 8822417Abstract: Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.Type: GrantFiled: May 4, 2012Date of Patent: September 2, 2014Assignee: Novozymes Biopharma DIC A/SInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Patent number: 8822145Abstract: Provided are isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.Type: GrantFiled: November 19, 2012Date of Patent: September 2, 2014Assignee: Ryogen LLCInventor: James Ryan
-
Patent number: 8822654Abstract: The present invention relates to the use of a composition including of at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.Type: GrantFiled: January 15, 2010Date of Patent: September 2, 2014Assignees: Universite Paris—Sud XI, Assistance Publique-Hopitaux de Paris, Universite Paris DescartesInventors: Delphine Borgel, Véronique Ferger, Elsa Bianchini, Nicolas Lerolle, Jean-Luc René Diehl
-
Patent number: 8822663Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.Type: GrantFiled: August 5, 2011Date of Patent: September 2, 2014Assignee: Moderna Therapeutics, Inc.Inventors: Jason P. Schrum, Stéphane Bancel, Noubar B. Afeyan
-
Publication number: 20140242049Abstract: A transformed T-cell for T-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the transfection of a gene for coding a chimera protein. The T-cell, to which the gene for coding the chimera protein is transected, may improve the therapeutic effects induced by immune tolerance of cancer cells, and furthermore maximize anti-cancer effects by activating signal transduction to induce the activation of T-cells. Also, the disclosure allows treatments that minimize side effects such as the development of autoimmune diseases due to systematic T-cell activation.Type: ApplicationFiled: October 26, 2012Publication date: August 28, 2014Applicant: NATIONAL CANCER CENTERInventors: Kyungho Choi, Jaehun Shin, Sang-Jin Lee
-
Publication number: 20140242701Abstract: Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.Type: ApplicationFiled: October 5, 2012Publication date: August 28, 2014Applicant: TAKARA BIO INC.Inventors: Hiroshi Shiku, Yuki Orito, Junichi Mineno, Sachiko Okamoto, Yasunori Amaishi
-
Publication number: 20140243237Abstract: The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.Type: ApplicationFiled: October 1, 2012Publication date: August 28, 2014Inventors: Kazutaka Ikeda, Daisuke Nishizawa, Kenichi Fukuda
-
Publication number: 20140242037Abstract: The invention relates to transgene expression constructs—particularly self inactivating lentiviral vectors—comprising a dendritic cell specific promoter controlling the expression of autoantigen proteins, namely myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein, for use in the therapy of multiple sclerosis.Type: ApplicationFiled: September 26, 2012Publication date: August 28, 2014Inventors: Christiane Dresch, Bruna de Andrade Pereira, Mathias Ackermann, Cornel Fraefel
-
Patent number: 8816052Abstract: Calcium-binding photoproteins showing the luminescence pattern with a slow decay of are desired. The invention provides a mutant apoprotein comprising an amino acid sequence wherein the 23rd to 34th amino acids in the amino acid sequence of SEQ ID NO: 2 are substituted with an amino acid represented by formula I below: Xaa23-Xaa24-Xaa25-Xaa26-Xaa27-Xaa28-Xaa29-Xaa30-Xaa31-Xaa32-Xaa33-Xaa 34; having a function to bind to the peroxide of coelenterazine or the peroxide of a coelenterazine analogue to form a photoprotein capable of emitting light under the action of calcium ions; and, having a half decay time of the luminescence emitted by binding of the photoprotein to calcium ions being not less than 2 seconds.Type: GrantFiled: March 27, 2012Date of Patent: August 26, 2014Assignee: JNC CorporationInventors: Satoshi Inouye, Yuiko Miura
-
Patent number: 8816057Abstract: Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.Type: GrantFiled: November 15, 2012Date of Patent: August 26, 2014Assignee: Senomyx, Inc.Inventors: Jon Elliot Adler, Sergey Zozulya, Xiaodong Li, Shawn O'Connell, Lena Staszewski
-
Patent number: 8815798Abstract: The present invention is related to insulin analogs containing additional disulfide bonds and methods of making such.Type: GrantFiled: June 21, 2011Date of Patent: August 26, 2014Assignee: Novo Nordisk A/SInventors: Svend Ludvigsen, Frantisek Hubalek, Thomas B. Kjeldsen, Tine N. Vinther
-
Publication number: 20140234945Abstract: The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.Type: ApplicationFiled: January 16, 2014Publication date: August 21, 2014Applicant: Amgen Inc.Inventors: Kenneth W. WALKER, Fei XIONG
-
Publication number: 20140237632Abstract: Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that, in certain embodiments, they are mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. In certain embodiments, the subject proteins are mutants of wild type Discosoma sp. “red” fluorescent protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms.Type: ApplicationFiled: January 21, 2014Publication date: August 21, 2014Inventors: BROOKE BEVIS, BENJAMIN GLICK
-
Publication number: 20140234311Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
-
Publication number: 20140235832Abstract: Described herein are kits for use in detecting RANKL polypeptides.Type: ApplicationFiled: May 2, 2014Publication date: August 21, 2014Applicant: IMMUNEX CORPORATIONInventor: Dirk M. ANDERSON
-
Publication number: 20140234827Abstract: The invention provides an isolated nucleic acid having a sequence encoding a spermidine/spermine acetyltransferase (“SSAT”), wherein translation of an mRNA comprising the encoded SSAT has increased basal translation and increased stimulated translation, compared to a wild-type mRNA encoding SSAT. Methods of use for the nucleic acid are also provided. Methods and compositions are also provided for reducing ischemia-reperfusion injury in organs or tissue for transplantation.Type: ApplicationFiled: August 31, 2012Publication date: August 21, 2014Applicant: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Salim Merali, Oscar Mauricio Perez Leal, Magid Abou-Gharbia, Wayne E. Childers
-
Publication number: 20140235475Abstract: A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment.Type: ApplicationFiled: June 25, 2012Publication date: August 21, 2014Inventor: Isabelle Carlavan
-
Publication number: 20140234348Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.Type: ApplicationFiled: September 24, 2012Publication date: August 21, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Nathalie Scholler, Katarzyna Urbanska, Daniel J. Powell, JR.
-
Publication number: 20140235538Abstract: The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.Type: ApplicationFiled: January 15, 2014Publication date: August 21, 2014Applicant: NOVARTIS AGInventors: David Jonathan GLASS, Mara FORNARO
-
Publication number: 20140235527Abstract: A pharmaceutical composition for regenerating an endothelial cell which includes as an active ingredient a DKK2 protein or a polynucleotide encoding the DKK2 protein, a pharmaceutical composition for preventing or treating erectile dysfunction, a method of regenerating an endothelial cell of a subject and a method of preventing or treating erectile dysfunction of a subject and which treat or prevent erectile dysfunction in a subject.Type: ApplicationFiled: April 10, 2012Publication date: August 21, 2014Applicant: INHA INDUSTRY PARTNERSHIP INSTITUTEInventors: Jun Kyu Suh, Ji Kan Ryu, Hai Rong Jin, Young Guen Kwon
-
Publication number: 20140228289Abstract: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).Type: ApplicationFiled: September 19, 2013Publication date: August 14, 2014Applicant: WYETH LLCInventors: Neil M. Wolfman, Soo Peang Khor, Kathleen N. Tomkinson
-
Publication number: 20140228558Abstract: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.Type: ApplicationFiled: September 23, 2013Publication date: August 14, 2014Applicant: GENEART AGInventors: David RAAB, Marcus Graf, Frank Notka, Ralf Wagner
-
Publication number: 20140228238Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.Type: ApplicationFiled: January 23, 2014Publication date: August 14, 2014Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke NAKAMURA, Toyomasa KATAGIRI, Shuichi NAKATSURU
-
Publication number: 20140227272Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Publication number: 20140230081Abstract: The present invention is in the field of molecular biology, more particularly, the present invention relates to nucleic acid sequences and amino acid sequences of a hamster C5aR1 and the use of hamster as an animal model for the characterization of complement system modulators within drug discovery.Type: ApplicationFiled: August 6, 2012Publication date: August 14, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Stefan Golz, Andreas Geerts, Maria Köllnberger